ArticleArchives of Razi Institute2022
Effect of Betaine on Blood Parameters Related to the Iron Status in Acrylamide-Treated Rats.
Article in Archives of Razi Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been well documented that acrylamide (ACR) is a human carcinogen. One of the consequences of ACR exposure is central and peripheral nervous system damage, which may lead to hallucinations, drowsiness, and numbness in the hands, as well as legs. Betaine (BET) plays an active role in methylation reactions, including DNA methylation, the integrity of cell membranes, and memory development. It has been approved that BET protects the liver from oxidative stress-inducing substances, such as ethanol, and nonalcoholic fatty liver, brain, kidney, stomach, as well as ovaries, in rats. Therefore, this study was designed to investigate how BET influences iron-related blood parameters and biomarkers in acrylamide-treated rats. Twenty adult rats, weighing 180-200 g and aging 6-7 weeks, were randomly divided into four equal groups and given the following treatments every day for 30 days. The control group was identified as G1. Animals in the G2 group were intubated with BET [250 mg/kg body weight (B.W.)]. Animals in the G3 group were intubated with ACR (1 mg/kg B.W.), while animals in the G4 group were intubated with both BET and ACR at the same doses as animals in G2 and G3 groups. At the end of the experiment, blood samples were collected from anesthetized rats using the cardiac puncture technique for measuring white blood cell count, as well as their differential count, red blood cells count, hemoglobin, and their related parameters, including mean corpuscular volume, mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin, hematocrit, as well as red cell distribution width. Additionally, serum was taken to measure serum iron concentration, ferritin, total iron-binding capacity, and transferrin saturation percentage. The results showed significant changes in some hematological parameters and the iron status correlated with anemia in the G3 group, treated with ACR. Such changes, accompanied by histopathological changes in the spleen oral intubation of BET alone, as well as its combination with ACR, caused the alleviation of anemia through correcting previous parameters. In conclusion, the findings revealed that BET positively influences anemia in rats treated with ACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.